Domainex has been granted a European Patent for its Combinatorial Domain Hunting (CDH) technology.
Based in London and Cambridge, Domainex is a research company developing a pipeline of pre-clinical drugs and targets, specialising in the development of novel drug targets reached by the CDH technology.
The company is also providing its structural biology and chemistry services to major pharmaceutical and biotechnology firms.
The vast amount of information available in the post-genomic era means there are many highly attractive protein targets known to the pharmaceutical industry where an inability to supply the protein has prevented its use in drug discovery.
Domainex has closed this discovery gap with its Combinatorial Domain Hunting (CDH) technology which enables the cloning and expression of recombinant proteins, or parts of proteins (domains), from challenging molecular targets.
These proteins are then screened to select soluble, stable protein domains that are ideal reagents for use in drug discovery programmes.
Domainex has already used its CDH protein expression platform to successfully tackle a series of difficult target proteins and has fulfilled commercial contracts with many pharmaceutical companies, such as UCB.
Domainex's portfolio will initially focus on targets for cancer treatments and it has started to discuss these targets with pharmaceutical companies with a view to future out-licensing.
Domainex also provides chemistry services to biotech and pharmaceutical firms involved in drug discovery.
